marketshareAI

Hikma Pharmaceuticals

HIKHealthcare
2,096.00GBX
-1.50%
Market Cap
4.62B
Volume
51.21k
10% of avg
P/E Ratio
11.78
EPS (TTM)
1.78
Beta
0.66
Day Range
2,096.00p - 2,130.00p
52 Week Range
1,751.00p2,096.00p2,360.00p
2,096.00p

Upcoming Events

July 9, 2025
Maturity of $500 million Eurobond
High Impact Event
7 August 2025
Announcement of interim results for the six months ended 30 June 2025
September 8, 2026
Amarin Pharma Inc. v. Hikma Pharmaceuticals PLC trial start date
High Impact Event
January 2030
Group revenue target of $5 billion
High Impact Event
HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding

The pharmaceutical company has disclosed a transaction by a Person Discharging Managerial Responsibilities.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding

The pharmaceutical company has disclosed a transaction by a Person Discharging Managerial Responsibilities.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director and PDMR Share Transactions

The pharmaceutical company has announced details of share transactions by its directors and other PDMRs following the vesting of conditional awards.

HIK
NEUTRAL

Hikma Pharmaceuticals Receives Fitch Upgrade to 'BBB' Rating

The pharmaceutical company receives an investment grade credit rating upgrade from Fitch.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director Share Transactions

The pharmaceutical company announces share transactions by its executive chairman, executive vice chairman, and non-executive director.

HIK
NEUTRAL

Hikma Pharmaceuticals Provides Medium-Term Guidance Ahead of US Site Visit

The pharmaceutical company has announced medium-term guidance for revenue and profit growth ahead of a site visit in the US.

HIK
NEUTRAL

Hikma Pharmaceuticals Directors Increase Shareholdings

The pharmaceutical company's directors have increased their shareholdings in the business through a dividend reinvestment plan.

HIK
NEUTRAL

S&P Upgrades Hikma Pharmaceuticals to 'BBB' Rating

The pharmaceutical company receives an upgrade to its credit rating from S&P, strengthening its investment grade status.

HIK
NEUTRAL

Hikma Reaches Settlement Agreement for Xyrem® US Lawsuits

The pharmaceutical company has reached a settlement agreement to resolve the majority of its Xyrem® (sodium oxybate) antitrust class action cases in the US, subject to court approval.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding

The pharmaceutical company has announced changes to director and PDMR shareholdings.